Skip to content
Imvax
  • Contact Us
  • Privacy/Terms
  • Join Our Team
Transforming Cancer OutcomesTM
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisors
  • Technology & Proprietary Methodologies
    • Patient Cell Harvest, Treatment, and Implant
    • Immunogenic Cell Death, Patient-Specific Antigens, Innate Immune System Activation
    • Long-term Adaptive Immune Activation and Response
  • Therapeutic Areas
    • Malignant Gliomas
  • Pipeline
    • IGV-001
  • Patients
  • News & Publications
  • Collaboration and Partnerships
Imvax
Home > News & Publications > Imvax Abstracts Accepted for Presentation at AACR 2021 Annual Meeting
  • Share
    •  
    •  
  • Print

Imvax Abstracts Accepted for Presentation at AACR 2021 Annual Meeting

Posted March 11, 2021March 11, 2021 Vera
Press-Release-AACR-4_031121

Post navigation

⟵ Imvax awarded $2M grant to build first of its kind cell processing center
Imvax Appoints Sean Hemingway as Chief Operating Officer ⟶

News

Stay informed about our latest
news and developments.

LEARN MORE

Patients

Our patients are the heart of our company, and they, along with their families, friends and caregivers, are just as much members of the Imvax Team.

LEARN MORE

601 Walnut St, Suite 440 W
Philadelphia, PA 19106

tel 267-900-4110

  • About Us
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Technology & Proprietary Methodologies
  • Patient Cell Harvest, Treatment, and Implant
  • Immunogenic Cell Death, Patient-Specific Antigens, Innate Immune System Activation
  • Long-term Adaptive Immune Activation and Response
  • Pipeline
  • IGV-001
  • Therapeutic Areas
  • Malignant Gliomas
close ×
IGV-001
  • Patients
  • News & Publications
  • Collaboration and Partnerships
  • Join Our Team
Website by Axxiem
© Copyright Imvax, Inc. All Right Reserved
Privacy/Terms | Sitemap